Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-098450
Filing Date
2024-11-14
Accepted
2024-11-14 16:15:45
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0219901-10q_estrella.htm   iXBRL 10-Q 834383
2 CERTIFICATION ea021990101ex31-1_estrella.htm EX-31.1 10540
3 CERTIFICATION ea021990101ex31-2_estrella.htm EX-31.2 10544
4 CERTIFICATION ea021990101ex32-1_estrella.htm EX-32.1 3937
5 CERTIFICATION ea021990101ex32-2_estrella.htm EX-32.2 3883
  Complete submission text file 0001213900-24-098450.txt   5083934

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE esla-20240930.xsd EX-101.SCH 49306
7 XBRL CALCULATION FILE esla-20240930_cal.xml EX-101.CAL 28678
8 XBRL DEFINITION FILE esla-20240930_def.xml EX-101.DEF 267175
9 XBRL LABEL FILE esla-20240930_lab.xml EX-101.LAB 427101
10 XBRL PRESENTATION FILE esla-20240930_pre.xml EX-101.PRE 262729
70 EXTRACTED XBRL INSTANCE DOCUMENT ea0219901-10q_estrella_htm.xml XML 512842
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40608 | Film No.: 241462543
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)